Neurocrine Biosciences Announces Conference Call and Webcast of First Quarter 2026 Financial Results

Neurocrine Biosciences (Nasdaq: NBIX) scheduled its Q1 2026 financial results release and conference call for May 5, 2026.

Rhea-AI Summary

Neurocrine Biosciences (Nasdaq: NBIX) scheduled its Q1 2026 financial results release and conference call for May 5, 2026. The press release will be at 1:00 p.m. PT / 4:00 p.m. ET and the live conference call at 1:30 p.m. PT / 4:30 p.m. ET.

Dial-in numbers and a webcast are provided; a replay will be available about one hour after the event and archived for approximately one month on the company's investors website.

Argus Apr 15 session

+0.48% close to close Open Argus

Details

News Market Reaction – NBIX

In the Apr 15 session, NBIX gained 0.48%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement sets the timetable and access details for NBIX’s Q1 2026 financial results, with t...

Analysis

This announcement sets the timetable and access details for NBIX’s Q1 2026 financial results, with the press release at 1:00 p.m. PT and a webcasted call at 1:30 p.m. PT on May 5. Historically, similar conferences,earnings notices have produced modest price moves averaging 0.88%. Investors following the story may focus more on upcoming earnings metrics and integration of the recently disclosed Soleno acquisition, as well as how results track against NBIX’s expanding neuroscience and endocrinology portfolio.

Key Figures

Q1 2026 press release time: May 5, 2026 at 1:00 p.m. PT / 4:00 p.m. ET Q1 2026 call time: May 5, 2026 at 1:30 p.m. PT / 4:30 p.m. ET Domestic dial-in: 800-274-8461 +5 more

Q1 2026 press release time

May 5, 2026 at 1:00 p.m. PT / 4:00 p.m. ET

Scheduled Q1 2026 financial results press release

Q1 2026 call time

May 5, 2026 at 1:30 p.m. PT / 4:30 p.m. ET

Scheduled Q1 2026 conference call and webcast

Domestic dial-in

800-274-8461

U.S. access number for Q1 2026 conference call

International dial-in

203-518-9814

International access number for Q1 2026 conference call

Conference ID

NBIX

Identifier for joining the Q1 2026 call

Webcast replay window

Approximately one month

Duration Q1 2026 webcast replay will be archived

Current share price

$126.32

Pre-announcement trading level

52-week range

$87.70–$160.18

Positioned 21.14% below 52-week high

Previous Conferences,earnings Reports

5 past events · Latest: Jan 21

Same Type 5 events

1. Jan 21

   Q4 2025 call setup

   24h Move

   +1.4%

   Announcement of timing and access details for Q4 and year-end 2025 results.

2. Oct 07

   Q3 2025 call setup

   24h Move

   +1.5%

   Scheduling of Q3 2025 earnings release and investor conference call/webcast.

3. Jul 09

   Q2 2025 call setup

   24h Move

   +1.1%

   Notice of Q2 2025 financial results release and related conference call.

4. Apr 14

   Q1 2025 call setup

   24h Move

   +1.3%

   Scheduling of Q1 2025 results press release and webcast for investors.

5. Jan 30

   Q4 2024 call setup

   24h Move

   -1.0%

   Announcement of Q4 and year-end 2024 earnings call and webcast logistics.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

webcast, tardive dyskinesia, Huntington's disease, congenital adrenal hyperplasia, +2 more

6 terms

webcast technical

"conference call and webcast for 1:30 p.m. Pacific Time..."

A webcast is a live or recorded online event where people watch or listen to presentations, announcements, or performances through the internet. It’s like a TV broadcast but over the internet, allowing viewers from anywhere to tune in in real time or later. Webcasts are important because they let companies share information quickly and widely with audiences around the world.

tardive dyskinesia medical

"FDA-approved treatments for tardive dyskinesia, chorea associated..."

A chronic movement disorder marked by repetitive, involuntary motions—often of the face, tongue, or limbs—that can develop after long-term use of certain psychiatric or neurological medications. It matters to investors because the condition creates medical need, regulatory scrutiny, potential for expensive treatments or liability, and can shape the commercial value of drugs in development or on the market; think of it as a persistent side effect that can change a drug’s price tag and sales prospects.

Huntington's disease medical

"treatments for tardive dyskinesia, chorea associated with Huntington's disease..."

A hereditary brain disorder caused by a faulty gene that progressively damages nerve cells, leading to uncontrollable movements, thinking and mood problems, and a shortened lifespan. It matters to investors because the disease creates a clear medical need and potential market for treatments, so news about clinical trial results, regulatory progress, or drug approvals can strongly move biotech and pharmaceutical stock values. Think of it as a predictable, inherited mechanical flaw in a complex machine that companies are trying to fix.

congenital adrenal hyperplasia medical

"classic congenital adrenal hyperplasia, endometriosis* and uterine fibroids*..."

Congenital adrenal hyperplasia is a group of inherited disorders in which the adrenal glands lack an enzyme needed to make certain hormones, causing a chronic imbalance of cortisol, aldosterone and/or sex hormones. Think of it as a factory assembly line missing a key part, so the body overproduces some products and underproduces others, requiring lifelong monitoring or hormone treatment. For investors, it matters because diagnosis, ongoing therapy, newborn screening and potential new drugs or gene therapies can drive medical spending, regulatory approvals and market opportunity in endocrinology and rare disease care.

endometriosis medical

"classic congenital adrenal hyperplasia, endometriosis* and uterine fibroids*..."

Endometriosis is a chronic condition where tissue similar to the lining of the uterus grows outside the uterus, often causing pain and fertility problems. It can impact a person's health and quality of life, potentially leading to increased healthcare costs and affecting workforce productivity. For investors, understanding conditions like endometriosis highlights the importance of healthcare innovations and markets related to women's health.

uterine fibroids medical

"classic congenital adrenal hyperplasia, endometriosis* and uterine fibroids*..."

Uterine fibroids are noncancerous growths that develop in the muscular wall of the uterus, often described like small rubbery lumps within the organ. They matter to investors because they affect a large number of people of reproductive age and drive demand for diagnostics, medications, minimally invasive procedures and surgical devices, creating revenue opportunities and regulatory, reimbursement and competitive considerations for healthcare companies.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Conference Call and Webcast Scheduled for Tuesday, May 5

SAN DIEGO, April 14, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it has scheduled its first quarter 2026 financial results conference call and webcast for 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time) on May 5, 2026.

The schedule for the press release and conference call / webcast is as follows:

• Q1 2026 Press Release: May 5, 2026 at 1:00 p.m. PT / 4:00 p.m. ET
• Q1 2026 Conference Call: May 5, 2026 at 1:30 p.m. PT / 4:30 p.m. ET
• Domestic Dial-In Number: 800-274-8461
• International Dial-In Number: 203-518-9814
• Conference ID: NBIX

The webcast can also be accessed on Neurocrine Biosciences' website under Investors at www.neurocrine.com. A replay of the webcast will be available on the website approximately one hour after the conclusion of the event and will be archived for approximately one month.

About Neurocrine Biosciences
Neurocrine Biosciences is a leading biopharmaceutical company with a simple purpose: to relieve suffering for people with great needs. We are dedicated to discovering and developing life-changing treatments for patients with under-addressed neurological, endocrine, psychiatric and immunological disorders. The company's diverse portfolio includes FDA-approved treatments for tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia, endometriosis* and uterine fibroids,* as well as a robust pipeline including multiple compounds in mid- to late-phase clinical development across our core therapeutic areas. For three decades, we have applied our unique insight into neuroscience and the interconnections between brain and body systems to treat complex conditions. We relentlessly pursue medicines to ease the burden of debilitating diseases and disorders because you deserve brave science. For more information, visit neurocrine.com, and follow the company on LinkedIn, X, Facebook and YouTube. (*in collaboration with AbbVie)

NEUROCRINE, the NEUROCRINE BIOSCIENCES Logo, and YOU DESERVE BRAVE SCIENCE are registered trademarks of Neurocrine Biosciences, Inc.

View original content to download multimedia:https://www.prnewswire.com/news-releases/neurocrine-biosciences-announces-conference-call-and-webcast-of-first-quarter-2026-financial-results-302742223.html

SOURCE Neurocrine Biosciences, Inc.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will Neurocrine (NBIX) release Q1 2026 results and hold the conference call?

The company will release Q1 2026 results on May 5, 2026 at 1:00 p.m. PT and hold a conference call at 1:30 p.m. PT. According to the company, the webcast begins at 4:30 p.m. ET and follows the press release timing.

How can investors join the NBIX May 5, 2026 conference call and webcast?

Investors can dial the domestic number 800-274-8461 or the international number 203-518-9814 and use Conference ID NBIX. According to the company, the event is also accessible via the investors section of neurocrine.com.

Will Neurocrine (NBIX) provide a replay of the May 5, 2026 webcast and for how long?

Yes; a replay will be available about one hour after the event and will be archived for approximately one month. According to the company, the replay will be posted on the investors section of its website.

What time should East Coast investors tune in for Neurocrine's Q1 2026 call (NBIX)?

East Coast investors should tune in at 4:30 p.m. ET for the live conference call on May 5, 2026. According to the company, the press release precedes the call at 4:00 p.m. ET on the same day.

Where will Neurocrine (NBIX) host the webcast for the May 5, 2026 results call?

The webcast will be hosted on the company's investors webpage at neurocrine.com. According to the company, the live webcast and subsequent replay will be available in the Investors section of the website.

What is the conference ID and international dial-in for Neurocrine's May 5, 2026 call (NBIX)?

The Conference ID is NBIX and the international dial-in number is 203-518-9814. According to the company, a domestic dial-in 800-274-8461 is also provided for U.S. callers.